THE-0504 in Patients With Solid Tumors
NANOFER-THE-0504: A Trial to Assess the Safety and Tolerability of an Investigational Drug THE-0504 for Patients With Solid Tumors
研究概览
详细说明
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Pierpaolo Ceci, PhD
- 电话号码:+39 0773822658
- 邮箱:pierpaolo.ceci@thenabiotech.com
研究联系人备份
- 姓名:Gennaro Daniele, PhD
- 电话号码:+39 0630157300
- 邮箱:gennaro.daniele@policlinicogemelli.it
学习地点
-
-
Lazio
-
Rome、Lazio、意大利、00168
- 招聘中
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
接触:
- Gennaro Daniele, PhD
- 电话号码:+39 0630157300
- 邮箱:gennaro.daniele@policlinicogemelli.it
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
Patients will be enrolled in the study if they meet all the following criteria:
- written informed consent obtained;
- both gender adult (≥ 18 years) patients;
- diagnosis of solid tumor. Preferably, but non-limited, tumor types are the following: Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Pancreas Adenocarcinoma (PaAdCa), Gastric Cancer (GC) and Triple Negative Breast Cancer (TNBrCa);
- measurable metastatic disease or locally advanced unresectable tumors;
- have exhausted all EMA-approved treatment options;
- ECOG Performance Status graded as 0 or 1;
- patients able to understand the full nature and the purpose of the trial, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire trial (ability to attend all the planned trial visits according to the time limits included) based on Investigator's judgement;
adequate liver function as assessed by following laboratory tests to be conducted within 28 days before the first dose of study treatment:
- Total bilirubin ≤ 1.5 × ULN (or ≤ 3 X ULN for patients with documented Gilbert-Meulengracht Syndrome, or for patients with hyperbilirubinemia considered due to liver metastasis).
- Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN (or ≤ 5 × ULN if due to liver involvement by tumor);
adequate kidney function as assessed by following laboratory test to be conducted within 28 days before the first dose of study treatment:
• Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min per 1.73 m2 according to the CKD-EPI formula.
adequate bone marrow function as defined as:
- Hgb ≥ 9 g/dL
- ANC ≥1.5x109/L
- PLT≥100.0 x109/L
- Female patients of childbearing potential and male patients who are sexually active with women of childbearing potential will have to mandatorily use an appropriate method of contraception, according to the definition of Note 3 of ICH M3 Guideline, for the entire duration of the trial and for a minimum of 12 months after last administration of the IMP.
Exclusion Criteria:
Patients will not be enrolled if they meet any of the following criteria:
- pregnant (as determined by a blood pregnancy test at the screening visit) or lactating women;
- male patients who are willing to father children during the trial or in the 12 months after the end of IMP administration;
- additional malignancy in the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy;
- have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic, but stable Grade 2 toxicities may be allowed to enrol after agreement between the Investigator and Sponsor;
- ECOG Performance Status > 2;
- had not tolerated previously administered Top1 inhibitor treatments;
- known active CNS metastatic disease (patients with CNS metastases that are treated with radiotherapy and are stable for at least 28 days before study treatment start could be considered eligible);
- serious concurrent illness;
- Hgb < 9 g/dL;
- Transfusion dependent anemia with transfusion dependency of ≥3 months;
- Clinically significant iron metabolism disorders (e.g., sickle cell anemia) or use of iron chelators treatments;
- Iron overload, hereditary hemochromatosis and similar;
- Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment;
- Prolonged QTc interval;
- Multiple Sclerosis (MS) or other demyelinating disease, Eaton-Lambert syndrome, history of haemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease;
- Non-healing wound(s), except for ulcerative lesions caused by the underlying neoplasm;
- History of severe allergic or anaphylactic reactions to previous protein-based therapy;
- Currently receiving anticoagulation therapy with warfarin;
Known history of HIV infection, unless all the following are applicable:
- receiving an approved, stable, effective combination antiretroviral therapy regimen for ≥ 3 months prior to the planned first study intervention;
- CD4 T-cell count > 350 cells/μL
- CD4 T-cell nadir (lowest historical count) > 350 cells/μL, and • viral load confirmed as < 50 copies/mL.
- HBV infection, unless on stable anti-viral therapy for > 4 weeks prior to the planned first dose of study intervention and viral load confirmed as undetectable; and HCV infection, unless the participant has received curative treatment and viral load was confirmed as undetectable;
- Known autoimmune disease, uncontrolled diabetes, vitiligo, or stable thyroid disease;
- Patients on chronic (more than 10 days) administration of systemic, high-dose corticosteroids (≥4 mg Dexamethasone or equivalent), not amenable for reduction or suspension;
- Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations;
- History of drugs and/or alcohol abuse;
- Patients considered to be unsuitable to participate, in the Investigator's opinion, for any other reason (e.g. consequences of previous medical and/or surgical procedures or other medical or ethical reasons);
- Planned relocation during the study, which would make impossible to attend the scheduled visits and follow-ups;
- Concomitant participation in other clinical trials or participation in the evaluation of any investigational drugs/products up to 4 weeks before this trial (in any case, enrolment procedure should start only after the complete washout of the drugs/products under investigation**); or previous participation in the same trial or planned to receive other investigational products during the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:治疗臂
|
THE-0504 will be administered intravenously according to the treatment regimen specified in the protocol.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Assessment of Maximum Tolerated Dose (MTD)
大体时间:From enrollment to completion of Cycle 1 (each cycle is 21 days)
|
From enrollment to completion of Cycle 1 (each cycle is 21 days)
|
|
Assessment of Recommended Phase 2 Dose (RP2D)
大体时间:During dose escalation, at the end of cycle 1 (each cycle is 21 days)
|
During dose escalation, at the end of cycle 1 (each cycle is 21 days)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Pharmacokinetic assessments of the IMP
大体时间:Pre-dose and up to 96 hours (30 minutes, 3 hours, 24 hours, 48 hours and 96 hours) post-dose of the first 3 Cycles (63 days)
|
Pre-dose and up to 96 hours (30 minutes, 3 hours, 24 hours, 48 hours and 96 hours) post-dose of the first 3 Cycles (63 days)
|
|
Uprising / incidence of anti-THE-05 antibodies (ADA)
大体时间:From baseline through Cycle 4 (84 days)
|
From baseline through Cycle 4 (84 days)
|
|
Objective Response Rate (ORR) according to RECIST 1.1
大体时间:From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months)
|
From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months)
|
|
Progression-Free Survival (PFS)
大体时间:From enrollment until disease progression or death from any cause (assessed up to 36 months)
|
From enrollment until disease progression or death from any cause (assessed up to 36 months)
|
|
Overall Survival (OS)
大体时间:From first IMP administration until death from any cause (assessed up to 36 months)
|
From first IMP administration until death from any cause (assessed up to 36 months)
|
|
Rate of patients with Complete Response (CR) or Partial Response (PR) according to RECIST 1.1
大体时间:From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months)
|
From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months)
|
|
Assessment of safety profile of the product THE-0504
大体时间:From first IMP administration through 90 days after last IMP administration
|
From first IMP administration through 90 days after last IMP administration
|
|
ECOG Performance Status changes from baseline
大体时间:From baseline through 90 days after last IMP administration
|
From baseline through 90 days after last IMP administration
|
合作者和调查者
调查人员
- 首席研究员:Gennaro Daniele、Fondazione Policlinico Universitario Agostino Gemelli IRCCS
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- THE-0504-001
- 2023-503787-17-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
To the present date, only the sharing of the summary of the clinical results after 30 months from the study completion can be guaranteed.
Complete data from individual participants cannot be shared in scientific publications until intellectual property of the Investigational Medicinal Product is granted in all countries currently under evaluation.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.